Phase I study of paclitaxel with oral etoposide in advanced solid tumors.

Abstract

PURPOSE This study evaluated dose escalation of paclitaxel administered as a 3-hour infusion after a fixed oral etoposide regimen given daily for 10 days to determine an optimal dose and a toxicity profile for this combination. PATIENTS AND METHODS Three consecutive cohorts consisting of 29 patients with measurable or assessable advanced solid tumors were… (More)

Topics

Cite this paper

@article{Perez1996PhaseIS, title={Phase I study of paclitaxel with oral etoposide in advanced solid tumors.}, author={Edith A. Perez and Taylor M. Coe and Corrine Turrell and Derick H. M. Lau and Donna L Campbell and David R. Gandara}, journal={The cancer journal from Scientific American}, year={1996}, volume={2 5}, pages={286-90} }